Remibrutinib-treated patients with CSU who achieve well-controlled disease activity reach this by week 3 in the majority of patients: Results from REMIX-1/-2 studies

M. Metz, M. Hide, W. Lai, S. Haemmerle, N. Chapman-Rothe, C-E. Ortmann, G. Mosnaim

Please use this <u>LINK</u> to access the publication once it has been presented at the congress

UCARE 2025, GA²LEN Urticaria Centers of Reference and Excellence (UCARE) Conference, 4–5 December 2025